Endometrial Cancer Lymphadenectomy Trial

Prior treatment

• preceding chemo-, radio, or endocrine therapy for EC
• any concomitant disease not allowing surgery including lymphadenectomy and/or chemotherapy

Other illness

• sarcomas (except for carcinosarcoma = malignant mixed Müllerian tumor)
• evidence of extrauterine disease by visual inspection
• any current medication containing considerable surgical risk (e.g. bleeding: due to oral anticoagulating agents)
• any known disorder or circumstances making participation in trial and follow-up questionable. Insufficient compliance is expected.
• patients with second malignancies if disease or treatment might have an impact on the patient's prognosis
• known HIV-infection or AIDS

Other

• stage pT1a, G1 or G2 tumors of type 1 histology
• EC of FIGO stages III or IV (except for microscopical lymph node metastases)
• recurrent EC
• any medical history indicating excessive peri-operative risk
• simultaneous participation in other clinical trials if not permitted by the steering committee (translational or QoL studies not interfering with the objectives of ECLAT are allowed)

• histologically confirmed EC of clinical stages T1b and T2 (all histological types) and stage T1a G3 type 1 (endometrioid, endometriod with squamous differentiation, mucinous) or type 2 tumors (any percentage of serous or clear cell component) or carcinosarcoma
• a) no previous surgery concerning EC (primary surgery) or b) surgery after hysterectomy (e.g. for presumed low risk endometrial cancer) is allowed within 8 weeks after hysterectomy if no LNE was performed (secondary surgery)
• absence of bulky lymph nodes
• performance status ECOG 0-1
• age 18 - 75 years
• written informed consent
• adequate compliance